力生製藥(002393.SZ):醫藥集團不再為公司間接控股股東
格隆匯10月31日丨力生製藥(002393.SZ)公佈,公司接到間接控股股東天津市醫藥集團有限公司(“醫藥集團”)通知,為落實天津市人民政府有關國有企業混合所有制改革的總體部署,醫藥集團擬將其持有的津聯集團100%股權無償劃轉至天津渤海國有資產經營管理有限公司(“渤海國資”);同時,將津聯集團通過其全資子公司金鼎控股持有的隆騰有限33%股權劃轉至醫藥集團境外全資子公司天津醫藥集團國際控股有限公司(“醫藥集團BVI公司”)。
醫藥集團與渤海國資於2019年10月31日簽署了《津聯集團有限公司100%股權無償劃轉協議》(“津聯集團劃轉協議”);同日,金鼎控股與醫藥集團BVI公司簽署了《隆騰有限公司33%股權無償劃轉協議》(“隆騰有限劃轉協議”),以上“津聯集團劃轉協議”和“隆騰有限劃轉協議”合稱為“劃轉協議”。
上述國有股權無償劃轉完成後,醫藥集團不再為公司的間接控股股東,渤海國資仍為公司的間接控股股東。劃轉完成後,公司的控股股東不變,仍為天津金浩醫藥有限公司(“金浩公司”),金浩公司對公司的持股數量及比例未發生變化;公司的實際控制人不變,仍為天津市人民政府國有資產監督管理委員會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.